Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 29;9(12):e14890. doi: 10.14814/phy2.14890

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Assessment of the impact of dapagliflozin (DAPA) treatment on real‐time renal microvascular P_kO₂ at different levels of inspired oxygen (F_IO₂) in non‐diabetic control or diabetic rats (protocol #1). (a) There was no significant difference in mean arterial pressure (MAP) between non‐diabetic control rats treated with vehicle or DAPA. (b) There was no significant difference in MAP between diabetic rats treated with either vehicle or DAPA, at any F_IO₂ level. (c) When assessed between groups over time, microvascular tissue oxygen was marginally lower in the control DAPA group relative to control vehicle (p = 0.012; two‐way ANOVA). (d) Renal microvascular P_kO₂ was significantly lower in diabetic rats treated with DAPA compared to vehicle‐treated diabetic rats (p < 0.001; two‐way ANOVA). The microvascular kidney P_kO₂ remained about 10 mmHg lower, in DAPA versus vehicle‐treated diabetic rats, at all F_IO₂ levels (n = 6–9 per group)